Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.


Journal Article

Data about the efficacy of ertapenem for the treatment of bloodstream infections (BSI) due to ESBL-producing Enterobacteriaceae (ESBL-E) are limited. We compared the clinical efficacy of ertapenem and other carbapenems in monomicrobial BSI due to ESBL-E.A multinational retrospective cohort study (INCREMENT project) was performed ( identifier: NCT01764490). Patients given monotherapy with ertapenem or other carbapenems were compared. Empirical and targeted therapies were analysed. Propensity scores were used to control for confounding; sensitivity analyses were performed in subgroups. The outcome variables were cure/improvement rate at day 14 and all-cause 30 day mortality.The empirical therapy cohort (ETC) and the targeted therapy cohort (TTC) included 195 and 509 patients, respectively. Cure/improvement rates were 90.6% with ertapenem and 75.5% with other carbapenems (P = 0.06) in the ETC and 89.8% and 82.6% (P = 0.02) in the TTC, respectively; 30 day mortality rates were 3.1% and 23.3% (P = 0.01) in the ETC and 9.3% and 17.1% (P = 0.01) in the TTC, respectively. Adjusted ORs (95% CI) for cure/improvement with empirical and targeted ertapenem were 1.87 (0.24-20.08; P = 0.58) and 1.04 (0.44-2.50; P = 0.92), respectively. For the propensity-matched cohorts it was 1.18 (0.43-3.29; P = 0.74). Regarding 30 day mortality, the adjusted HR (95% CI) for targeted ertapenem was 0.93 (0.43-2.03; P = 0.86) and for the propensity-matched cohorts it was 1.05 (0.46-2.44; P = 0.90). Sensitivity analyses were consistent except for patients with severe sepsis/septic shock, which showed a non-significant trend favouring other carbapenems.Ertapenem appears as effective as other carbapenems for empirical and targeted therapy of BSI due to ESBL-E, but further studies are needed for patients with severe sepsis/septic shock.

Full Text

Cited Authors

  • Gutiérrez-Gutiérrez, B; Bonomo, RA; Carmeli, Y; Paterson, DL; Almirante, B; Martínez-Martínez, L; Oliver, A; Calbo, E; Peña, C; Akova, M; Pitout, J; Origüen, J; Pintado, V; García-Vázquez, E; Gasch, O; Hamprecht, A; Prim, N; Tumbarello, M; Bou, G; Viale, P; Tacconelli, E; Almela, M; Pérez, F; Giamarellou, H; Cisneros, JM; Schwaber, MJ; Venditti, M; Lowman, W; Bermejo, J; Hsueh, P-R; Mora-Rillo, M; Gracia-Ahulfinger, I; Pascual, A; Rodríguez-Baño, J; REIPI/ESGBIS/INCREMENT Group,

Published Date

  • June 2016

Published In

Volume / Issue

  • 71 / 6

Start / End Page

  • 1672 - 1680

PubMed ID

  • 26907184

Pubmed Central ID

  • 26907184

Electronic International Standard Serial Number (EISSN)

  • 1460-2091

International Standard Serial Number (ISSN)

  • 0305-7453

Digital Object Identifier (DOI)

  • 10.1093/jac/dkv502


  • eng